By the time a visual identity is developed or messaging is written, much of the brand’s trajectory has already been set.
When it comes to true differentiation, the real issue starts earlier in the structure of the name itself.
The Invisible Starting Point
Across the pharmaceutical industry, naming systems are becoming increasingly efficient, but also increasingly similar.
With the repeated use of the same linguistic building blocks:
- Familiar prefixes
- Common suffixes
- Modular word parts
- Predictable semantic structures
Individually, these tools serve a purpose. They help streamline regulatory approval, improve internal alignment, and accelerate timelines.
But at scale, they introduce a deeper structural issue. The same components are being reused across multiple brands leading to less differentiation and uniqueness.
The Result: Structural Convergence
Even when the underlying science is different, brand names begin to follow the same architecture.
This is difficult to detect because:
- Names still sound distinct
- Approvals are still achieved
- Stakeholders still perceive variation
But beneath the surface, the system is repeating itself.
Rethinking Naming as a System
Most teams treat naming as the endpoint, a stamp of approval. A brand name is the one identifier that remains constant throughout the life of a product.
The goal isn’t just to create a name that works in isolation, it’s to build a linguistic foundation that can carry meaning consistently across the brand.
That may include, but is not limited to:
- Mechanism of action
- Patient context
- Emotional and narrative intent
When naming is approached this way, it becomes a system — not just a label. Once the pillars are set, it’s time to move onto the visual identity.